Skip to main content
. Author manuscript; available in PMC: 2023 Oct 1.
Published in final edited form as: J Pain. 2022 Jun 10;23(10):1629–1645. doi: 10.1016/j.jpain.2022.05.009

Figure 1.

Figure 1.

Experimental design. A. The baselines of the thermal withdrawal latency (T), mechanical withdrawal threshold (M) and maxillofacial mechanical threshold (F) were tested before UAC. From the first day after UAC was established, the thermal withdrawal latency and mechanical withdrawal threshold were measured on the first and second days and then every 8 days. On day 3 after UAC was established, the maxillofacial mechanical threshold was tested, and then every 4 days. The measurement continued until the pain threshold returned to the baseline level. UAC, unilateral anterior crossbite. CCK1 receptor antagonist loxiglumide (B) or IL-18-binding protein (IL-18BP) (C) was intrathecally injected for 5 consecutive days at 4 weeks post UAC.